CINGW

Cingulate Inc.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001862150 Biotech & Drug Discovery

Warrants of Cingulate Inc. · CING stock page →

—

Market cap

$145.4K

Nano cap

1 year

+36.0%

from $3.76 · Oct 27

30 days

+6.1%

from $4.82

52-week range

$3.33–11.66

−56% from high · low Nov 13

Avg volume 20D

90.0K

Oct 16 spike 228.6K

Short interest

864

≈0.0% of shares · −35.2%

Days to cover

1.0

at average volume

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BEARISH 5 reports · latest

Balance 2 bearish · 0 bullish · 3 neutral oldest → newest, height = score

Avg score

·High conf. 5/5

Strongest BEARISH Cingulate received a Complete Response Letter (CRL) from the FDA for its lead NDA, CTx-1301 (ADHD), citing…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Mar 18 Cingulate Inc. reported its Q4 and full-year 2025 financial results,…
R Apr 27 Cingulate Inc.'s S-3 shelf registration has become effective, allowi…
R Jun 2 Cingulate received a Complete Response Letter (CRL) from the FDA for…
X Jul 15 Short interest jumps 283.0% to 1.1K
X Jul 31 Short interest falls 36.0% to 735
X Aug 14 Short interest jumps 705.4% to 5.9K
X Aug 31 Short interest falls 74.1% to 1.5K
X Sep 30 Short interest falls 35.2% to 864

Signal stack

Where each data set points today.

InstitutionsMIXED

Q2 2026: 1 added (0 new), 0 trimmed or exited.
Short sellersCOVERING

Short interest −35.2% to 864 shares. 1.0 days to cover, ≈0.0% of shares.
TrendRANGE

2% above its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
CAPTRUST FINANCIAL ADVISORS	DOUBLED	35,200	$672.00
UBS Group AG	TRIM	580	$17.00
UBS Group AG	TRIM	1,493	$82.00
CITADEL ADVISORS LLC	ADD	19,479	$1.8K

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Recent

Sep 17, 2026

Press release

Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma

Chief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size Pharma Chief Commercial…

Aug 13, 2026

Earnings

Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Cash and Cash Equivalents of $28.4 Million as of June 30, 2026 Providing Runway Through Mid-2027; Company Advances Chemistry, Manufacturing and…

Jul 2, 2026

Press release

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®

CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors CEO Shane Schaffer: Inclusion…

May 14, 2026

Earnings

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Cash Position Grows to $25.9 Million Cash Position Grows to $25.9 Million

Mar 18, 2026

Earnings

Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

U.S. Patent Notice of Allowance for CTx-1301 Received; Additional European Patents Granted Recent $12M Private Placement Closed At-the-Market…

Earnings setup

Estimates

Period	EPS est.	Range	30D rev.	Revenue
Current Q	—	—	—	$0.00
Next Q	—	—	—	$0.00
Current FY	—	—	—	$0.00
Next FY	—	—	—	$22.3M

Short side

FINRA· Sep 30, 2026

864

shares short

-35.2%

vs prior settlement

1.0

days to cover

≈0.0%

of shares outstanding

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Sep 17, 2026 Other

Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma

Chief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for

Jun 30, 2026 Inst.

CAPTRUST FINANCIAL ADVISORS — DOUBLED

35,200 shares ($672.00)

Jun 2, 2026 SEC

Cingulate received a Complete Response Letter (CRL) from the FDA for its lead NDA, CTx-1301 (ADHD), citing only…

8-K — Impact 7/10

May 19, 2026 SEC

Cingulate reported that Class II directors Jeff Ervin and Jay Roberts will not stand for re-election at the 2026…

8-K — Impact 2/10

May 14, 2026 SEC

Cingulate Inc. reported Q1 2026 results with a net loss of $9.3M, widening from a $3.9M loss in Q1 2025, driven by a…